Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6DD88
UPID:
ATLA3_HUMAN
Alternative names:
-
Alternative UPACC:
Q6DD88; Q8N7W5; Q9H8Q5; Q9UFL1
Background:
Atlastin-3 plays a crucial role in the formation of the endoplasmic reticulum's tubular network by tethering membranes through trans-homooligomer formation and mediating homotypic fusion. Its involvement in endoplasmic reticulum biogenesis is vital for cellular function.
Therapeutic significance:
Atlastin-3's mutation is linked to Neuropathy, hereditary sensory, 1F, a disease affecting lower limbs' sensory nerves. Understanding Atlastin-3's role could lead to novel therapeutic strategies for this debilitating condition.